London-based Alchemab Therapeutics Closes Series A Ext. Backed by Ono Venture and Lilly
This article covers a Series A extension on 9 September 2025 at Alchemab Therapeutics, a London-based biopharmaceutical company that identifies and develops naturally occurring therapeutic antibodies from resilient individuals, led by CEO Jane Osbourn. The raise brought the total to $114m, with Ono Venture Investment as lead investor and RA Capital also investing.
What does Alchemab Therapeutics do?
The product is a discovery platform that identifies and develops naturally occurring therapeutic antibodies from resilient individuals. It is used to identify targets and advance lead candidates into clinical development.
Why is Alchemab Therapeutics useful?
Problem
Patients with hard-to-treat diseases like muscle atrophy lack disease-modifying therapies and effective antibody treatments.
Solution
Alchemab identifies naturally occurring antibodies from resilient individuals and finds their targets using data mining and lab studies. It develops those antibodies into therapies, advancing ATLX-2847 for muscle atrophy into clinical development.
How much did Alchemab Therapeutics raise?
Alchemab Therapeutics raised an undisclosed amount in a Series A extension, backed by Ono Venture Investment (OVI) and strategic investor Lilly, bringing total funding to approximately Ā£90M ($114M).
Who invested in Alchemab Therapeutics?
Key investors in the deal include:
- Ono Venture Investment (OVI): the corporate venture arm of Ono Pharmaceutical, investing in innovative therapeutics and strategic collaborations.
- RA Capital: a US-based life sciences investor that backs biotech and healthcare companies, known for supporting translational and clinical-stage ventures.
- SV Health Investors: a healthcare-focused venture firm active across Europe and the US, specialising in early and growth-stage life sciences investments.
- DCVC Bio: a US investor concentrating on deep tech and biosciences, supporting platform companies that combine computational and biological approaches.
- Lightstone Ventures: a UK-based investor concentrating on early-stage life sciences and therapeutics, with a focus on science-driven startups.
- Lilly: the pharmaceutical company made a strategic investment and can provide development and commercial expertise to portfolio partners.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Who founded Alchemab Therapeutics?
Jane Osbourn is the CEO of Alchemab Therapeutics.
Where is Alchemab Therapeutics based?
Alchemab Therapeutics is based in London, UK.
What sector is Alchemab Therapeutics in?
Alchemab Therapeutics operates in the biopharmaceutical sector. This sector researches and develops medicines from biological sources.
Key trends and challenges in biopharmaceutical sector:
Human-derived antibody discovery
Researchers mine resilient peopleās immune responses to find therapeutic antibodies, for example monoclonal drugs like adalimumab.
Focus on first in class treatments for unmet needs
Biopharma increasingly targets first in class drugs for unmet needs like muscle atrophy and neurodegeneration.
High clinical failure rates and development risk
About 90% of drug candidates fail during clinical trials, raising time and cost risks.
For a deeper look at innovation in this space, see the biotech startups in the UK.
They've invested in Alchemab Therapeutics
Get to know these biotech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 Ono Venture Investment (OVI) | 1 investment investment | more info | |||
 RA Capital | 3 investments investments | more info | |||
 SV Health Investors | 7 investments investments | 6 contacts contacts | |||
 DCVC Bio | 1 investment investment | more info | |||
 Lightstone Ventures | 1 investment investment | more info | |||
 Eli Lilly & Company (Lilly) | 3 investments investments | 1 contact contact |
Click here for a full list of 7,526+ startup investors in the UK